Company Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers.
It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers.
Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer.
The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
Country | United States |
Founded | 2014 |
IPO Date | Dec 19, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 10 |
CEO | Chandler Robinson |
Contact Details
Address: 1000 Skokie Boulevard, Suite 350 Wilmette, Illinois 60091 United States | |
Phone | 847 388 0349 |
Website | monopartx.com |
Stock Details
Ticker Symbol | MNPR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $8.00 |
CIK Code | 0001645469 |
CUSIP Number | 61023L108 |
ISIN Number | US61023L1089 |
Employer ID | 32-0463781 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | Co-Founder, Chief Executive Officer, President and Director |
Dr. Christopher M. Starr Ph.D. | Co-Founder and Independent Executive Chairman of the Board |
Andrew J. Cittadine M.B.A. | Chief Operating Officer |
Karthik Radhakrishnan CFA | Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer |
Dr. Patrice P. Rioux M.D., Ph.D. | Acting Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 31, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Oct 30, 2024 | 8-K | Current Report |
Oct 29, 2024 | 424B5 | Filing |
Oct 28, 2024 | 424B5 | Filing |
Oct 28, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Oct 24, 2024 | 8-K | Current Report |
Oct 22, 2024 | 8-K | Current Report |
Oct 15, 2024 | 8-K | Current Report |
Oct 7, 2024 | 8-K | Current Report |